News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiovascular BioTherapeutics, Inc. (CVBT.OB) Engages The Bruckner Group To Find A Joint Commercialization Partner For Its FGF-1 Protein Treatment For Severe Heart Disease


11/28/2007 10:20:41 AM

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) has engaged The Bruckner Group (BGI) to assist CVBT in finding a joint commercialization partner for its drug candidate CVBT-141H to treat severe coronary heart disease (CHD). The drug contains the active pharmaceutical ingredient (API) human fibroblast growth factor -1 (FGF-1).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES